Strand Life Sciences Secures Patent for Revolutionary Cancer Detection Platform

Strand Life Sciences Secures Patent for Revolutionary Cancer Detection Platform

Read more about Strand Life Sciences Secures Patent for Revolutionary Cancer Detection Platform on Devdiscourse.

Reliance's Strand Life Sciences secures Indian patent for blood-based early cancer detection

The patented platform combines genome sequencing, methylation analysis and machine learning to detect cancer and identify its tissue of origin from a single blood sample.

Reliance’s Strand Life Sciences gets patent for blood-based early cancer detection

Reliance’s Strand Life Sciences patents a blood-based technology for early cancer detection, enhancing accuracy and accessibility.

Reliance's Strand Life Sciences Secures Indian Patent for Blood-based Early Cancer Detection Technology

Get latest articles and stories on Business at LatestLY. Strand Life Sciences, a subsidiary of Reliance Industries Limited, has been granted an Indian patent for its integrated platform that enables early cancer detection from a simple blood test using cell-free DNA (cfDNA) analysis, the company said in a press release on Tuesday. Business News | Reliance's Strand Life Sciences Secures Indian Patent for Blood-based Early Cancer Detection Technol…

Reliance’s Strand Life Sciences secures Indian patent for liquid biopsy platform

More than 1.5 million new cancer cases are estimated to occur annually, and several patients are still diagnosed at advanced stages

New cfDNA patent could scale early-stage cancer diagnosis in India

A new patent for a blood-based cancer screening platform promises to make precision oncology more accessible through AI-enabled genome sequencing